

Art Unit: 1642

56. (Currently Amended) The vaccine composition according to ~~claim 54~~ claim 1, ~~wherein the vector furthermore comprises nucleic acids encoding~~ comprising a T-cell stimulatory polypeptide.

Claims 66, 71-75, and 81 have been canceled.

CF 8-S-10

Claim 88, line 2, "if at all," has been deleted.

Claim 89, line 2, "nonetheless" has been deleted.

CF 8-S-10

Claim 91, line 2, "if at all," has been deleted.

Claim 92, line 2, "nonetheless" has been deleted.

Withdrawn claims 29, 30, 50, and 51, and 56 and 57 are rejoined and allowed.

The following is an examiner's statement of reasons for allowance: The new claims 88 and 91 have support in original claim 37, which lists the anchor positions of HLA-A2 be to at 2, 6, and the C terminal residues (position 10 in case of SEQ ID NO: 8), and the specification on page 40, Table 1 discloses that the testing of the various peptides with HLA-A2.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably